Major Adverse Cardiovascular Events (MACE) Risk in Coronary Artery Disease (CAD)
An elevated risk of major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) indicates a higher near- and/or long-term likelihood of cardiovascular death and nonfatal myocardial infarction (MI), reflecting more advanced coronary atherosclerosis and higher-risk clinical phenotypes. [1][2] MACE risk stratification is used to align intensity of guideline-directed medical therapy (GDMT) and the need for additional diagnostic evaluation with expected event rates. [1][2]
Prognostic Meaning of Elevated MACE Risk
Elevated MACE risk indicates that obstructive coronary lesions and associated myocardial ischemia are more likely to drive subsequent events. [1][2] Risk features used for prognostication overlap with those used to determine disease severity, including clinical symptoms, functional ischemia, and coronary anatomic burden. [1][2]
Established MACE Risk Categories in Chronic Coronary Disease
For chronic coronary disease, risk can be stratified by estimated annual MACE risk into low (<1% annual risk), intermediate (1% to 3% annual risk), and high (>3% annual risk). [1] These categories correspond to progressively greater expected event rates and progressively stronger justification for more intensive management. [1]
Clinical Features Associated With Higher MACE Risk
Anginal symptoms during noninvasive testing are associated with increased risk of MACE compared with silent ischemia. [1] Higher plaque burden and more severe coronary stenosis are recognized prognostic markers for adverse outcomes. [2]
Anatomic and Ischemia Burden Indicators
The number of markedly obstructive coronary arteries and the presence of left main disease are key determinants of prognosis in obstructive chronic coronary syndromes. [2] High-risk anatomic thresholds are supported by evidence summarized in guideline recommendations, including coronary stenosis extent and left main stenosis cut points. [2]
Implications for Management Intensification
In patients with chronic coronary disease, optimization of GDMT is recommended to reduce MACE. [1] In patients with newly reduced left ventricular systolic function or clinical heart failure, invasive coronary anatomy assessment is recommended to guide potential revascularization decisions. [1] In patients without left ventricular systolic dysfunction, heart failure, stable chest pain refractory to GDMT, or noninvasive testing suggestive of significant left main disease, invasive coronary angiography for risk stratification is not routinely recommended. [1]
Targets for Risk Reduction Goals
Risk reduction strategies in chronic coronary disease aim to lower the probability of cardiovascular death and nonfatal MI as captured within the MACE construct used for prognostication. [1]
Common Pitfalls in Interpreting “Elevated Risk”
Risk estimates can be driven by disease severity markers that are not fully captured by symptoms alone, including ischemia burden and coronary anatomic extent. [1][2] Interpreting elevated MACE risk without aligning management intensity with measured severity can lead to under-treatment of modifiable risk and inappropriate use or nonuse of additional evaluation. [1][2]
MACE Risk as a Trigger for Appropriate Reassessment
Elevated MACE risk supports reassessment of disease severity using the same clinical, noninvasive, and invasive investigations used to define obstructive CAD and related high-risk features. [2]